ARCHIVES

Zelboraf Increased Overall Survival To 15.9 Months in Phase II Study

This article is from The Cancer Letter archive.

Vol. 35 No. 3 | March 30, 2012

Download PDF Visit The Full Archive

Related Articles

Clearinghouse Exec. Secty, Says It Has Failed in Its Objectives, Recommends It Be Dropped

January 13, 1978

NCI Cooperative Group Clinical Trials Approved

February 26, 2010

Schmidt Attempted To Answer Critics

October 1, 1976

Children’s Oncology Group to Select New Chairman; Four Leaders to Step Aside

April 28, 2000

Funding Opportunities (12-page issue).

May 16, 2003

Trial Combines Drugs Against Blood Vessel Formation

October 26, 2007